Peptide Therapy : Specific peptides, such as Ipamorelin or Tesamorelin, can be strategically utilized to stimulate Growth Hormone Release, promoting lean mass preservation and supporting healthy body composition changes while the GLP-1 drug drives fat loss
Hypothyroidism, Cushing's syndrome, polycystic ovary syndrome (PCOS), perimenopause, obstructive sleep apnoea, or other hormonal imbalances may impede weight loss despite appropriate medication
On average, people lose 22% of their body weight on Mounjaro 15mg, compared to 21% on Wegovy 7.2mg
Doctors sometimes refer to that imbalance as sarcopenic obesity a higher proportion of body fat paired with reduced muscle mass
Dehydration is a particular concern when combining antibiotics with GLP-1 therapy, since infections increase fluid loss and semaglutide can reduce appetite-driven fluid intake
It is also explicitly named on the WADA Prohibited List at S2.2.4 and is prohibited in sport at all times